

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**  
**ENTERED INTO EXCLUSIVE COMMERCIAL COOPERATION AGREEMENT**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**” or “**Sino Biopharm**”) announces that Chia-Tai Tianqing Pharmaceutical Group Co., Ltd., a subsidiary of the Company, entered into an exclusive commercial cooperation agreement with Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. (“**ProteLight Pharmaceutical**”) for PL-5, an antimicrobial peptide product for the treatment of secondary wound infections, in China.

PL-5 is the first newly designed non-antibiotic antimicrobial drug with a broad antibacterial spectrum. It has excellent efficacy against local open wound infections, especially against drug-resistant strains without developing new drug-resistant bacteria, therefore it has huge market potential and wide application prospects. The product has completed a phase III clinical study in China for the treatment of secondary wound infections.

This cooperation allows PL-5 to leverage on the strong commercial promotion and sales capabilities of Sino Biopharm to help patients in China suffering from secondary wound infections to benefit from PL-5 as early as possible.

**About PL-5**

PL-5 is an antimicrobial peptide designed from scratch for the treatment of secondary wound infections. Secondary wound infections are open wound infections caused by various bacteria, including diabetic foot, decubitus ulcers and burns. With the use of antibiotics, the proportion of drug-resistant bacteria is increasing, causing a more serious problem of colonization of pathogenic bacteria, and the continuous evolution of antibiotic resistance requires systematic antibacterial treatment, especially for the local antibacterial treatment of the infection sites. PL-5 is a new antimicrobial peptide molecule obtained

by applying the theory of “cell membrane differentiation mechanism” based on the cell membrane structure and composition and by using the antimicrobial peptide research and development platform of ProteLight Pharmaceutical, which has a wide antimicrobial spectrum with very strong bactericidal advantage against a variety of drug-resistant bacteria, including methicillin-resistant *Staphylococcus aureus* (MRSA) and multi-drug-resistant *Acinetobacter baumannii* containing NDM-1 gene. PL-5 has completed clinical phase III study and observed good clinical effect, and is expected to become an important treatment option for secondary wound infections in the future.

### **About ProteLight Pharmaceutical**

Founded in 2009 and located in Jiangyin City, Jiangsu Province, ProteLight Pharmaceutical focuses on the research, development and production of first-in-class innovative peptide drugs, and is committed to becoming a leading international anti-infective peptide pharmaceutical enterprise. With the core development strategy of innovative drug research and development at source, ProteLight Pharmaceutical has developed a variety of first-in-class new peptide drug research and development pipelines led by category I anti-infective new drugs, and accumulated a number of national category I innovative drug projects under research.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 3 January 2023

*As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*